Our Pipeline

Our Pipeline
With Promise

Portfolio In Development

EQRx has more than 10 programs in our portfolio of potential medicines, including both small molecules and biologics, with five clinical-stage programs, and several preclinical and drug engineering programs. We strive to create best-in-class medicines that can make a meaningful impact for patients.

In order to assemble our portfolio, our current clinical-stage assets were in-licensed from biopharma companies around the world. In addition, we have entered into multiple drug engineering collaborations with leading technology platform companies, including those with technology-enabled experimental platforms, machine-learning computational platforms, and physics-based computational platforms, to efficiently engineer molecules against well-specified targets for important chronic and life-threatening conditions.


Ongoing Trials

Planned Trials

Program Target


EGFR-mutated metastatic or locally advanced NSCLC

Phase 3

Adjuvant therapy in EGFR-mutated

Phase 3


1L / 2L advanced
breast cancer

Phase 2

Metastatic endometrial cancer

Phase 3


1L metastatic NSCLC

Phase 3

Consolidation therapy in locally
advanced/unresectable NSCLC

Phase 3


Hepatocellular carcinoma

Phase 3



Phase 2

The safety and efficacy of these investigational compounds have not been established. There is no guarantee that the outcome of these studies will result in approval by a regulatory authority.

This pipeline describes investigational assets as of 2/23/2023.

View our Expanded Access Policy.

Abbreviations: 1L = first-line; 2L = second-line; CDK4/6 = cyclin-dependent kinase 4 and 6; EGFR = epidermal growth factor receptor; ENKTL = extra-nodal natural killer/T-cell lymphoma; JAK1 = Janus kinase 1; NSCLC = non-small cell lung cancer; PD-1 = programmed-death-1; PD-L1 = programmed death ligand-1.

Follow @EQRx_Global on Twitter for #RemakingMedicine updates

Remaking Medicine

Learn about
our leaders

Our Leadership
Go to EQRx global home page

This site is intended for a global audience but it may not be suitable for some countries.
Choose the US Site for info specific to the United States.

© 2023 EQRx, Inc. and its subsidiaries. EQRx and Remaking Medicine are trademarks of EQRx.

Trademarks on this website are protected by registration and common law rights in many countries throughout the world.

MED-00110 | February 2023